STING1 and neoplasm: STING agonist-loaded exosomes suppressed the growth of B16F10 melanoma tumor cells in vivo and demonstrated enhanced delivery to DCs compared with the STING agonist alone, which resulted in an increased recruitment of activated CD8+ T-cells and enhanced anti-tumor immune response [48].